Skip to content
AnalystLens

BridgeBio Pharma Quarterly Report for Q3 Ended Sep 30, 2024

Filing Date
Filed November 12, 2024
Period End
September 30, 2024
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 10-Q filed November 12, 2024. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (BridgeBio) reported a net loss of $164.3 milliona for the three months ended September 30, 2024 and $276.0 million for the nine months, compared with $482.9 million for the nine months ended September 30, 2023.

Revenue for the nine months rose to $216.0 millionb from $7.6 million, driven mainly by $205.3 million of upfront license fee and services revenue under the Bayer Agreement and the KKC Agreement, while three-month revenue was $2.7 million. Cash and cash equivalents were $266.3 million and restricted cash was $139.4 million at September 30, 2024, and total stockholders' deficit was $1.22 billion. Net cash used in operating activities was $325.4 million for the nine months.

The filing states that substantial doubt exists about the company's ability to continue as a going concern for one year from November 12, 2024. Management plans to alleviate this doubt by receiving a $500.0 millionc milestone payment under the Funding Agreement upon FDA approval of acoramidis, together with product revenues if approved. The company anticipates FDA approval in late November 2024 but cannot guarantee the approval, the timing of the payment, or the resulting product revenues, and may need to raise additional capital.

During 2024 the company restructured its portfolio: it deconsolidated GondolaBio and BBOT (TheRas, Inc.), recognizing gains of $52.0 milliond and $126.3 million respectively, ceased development of BBP-631 for congenital adrenal hyperplasia, and terminated the Navire-BMS License Agreement. Its outstanding debt was $1.7 billion, including $747.5 million of 2029 Notes, $550.0 million of 2027 Notes, and a $450.0 million term loan under the Amended Financing Agreement, with a $70.0 million minimum qualified cash balance that was $78.0 million as of September 30, 2024.

Key Highlights

  1. Nine-month net loss of $276.0 million, down from $482.9 million in the prior-year period, with three-month net loss of $164.3 million.
  2. Nine-month revenue of $216.0 million versus $7.6 million a year earlier, mainly from the Bayer and Kyowa Kirin license agreements.
  3. Substantial doubt about the company's ability to continue as a going concern, which management plans to address with the $500.0 million FDA-approval milestone payment under the Funding Agreement.
  4. Cash and cash equivalents of $266.3 million plus restricted cash of $139.4 million as of September 30, 2024, versus $375.9 million and $16.7 million at December 31, 2023.
  5. Total stockholders' deficit of $1.22 billion and total liabilities of $1.88 billion as of September 30, 2024.
  6. Gains on deconsolidation of $178.3 million for the nine months, including $52.0 million from GondolaBio and $126.3 million from BBOT, plus $27.5 million of net other income for the quarter.
  7. Debt of $1.7 billion, including the 2029 Notes, 2027 Notes, and a $450.0 million variable-rate term loan with a $70.0 million minimum cash covenant.

Financial Statements

Q3 FY2024 against Q3 FY2023

Line itemQ3 FY2024Q3 FY2023Change
Revenue$2.73M$4.09M−33.2%
Cost of Revenue$598K$598K0.0%
Gross Profit$2.13M$3.49M−38.9%
R&D Expenses$120.44M$125.14M−3.7%
SG&A Expenses$68.82M$35.78M+92.4%
Operating Expenses$194.48M$161.78M+20.2%
Operating Income-$191.75M-$157.69M−21.6%
Interest Expense$8.59M$8.56M+0.3%
Net Income-$162.04M-$177.00M+8.5%
EPS (Basic)$-0.86$-1.08+20.4%
EPS (Diluted)$-0.86$-1.08+20.4%
Shares Outstanding (Basic)188.51M163.31M+15.4%
Shares Outstanding (Diluted)188.51M163.31M+15.4%

Frequently Asked Questions

  1. Why does the filing raise substantial doubt about the company's ability to continue as a going concern?

    The company cites its history of recurring operating losses since inception and its expectation of continuing losses. Management says it plans to alleviate the doubt with the $500.0 million milestone payment under the Funding Agreement, which is payable upon FDA approval of acoramidis, together with product revenues if approved. The filing states the company cannot guarantee approval, timely payment, or the expected revenues, and may need to raise additional capital.

  2. What drove the large increase in revenue for the nine months ended September 30, 2024?

    The filing attributes $205.3 million of the nine-month revenue to the upfront license fee and services revenue under the Bayer Agreement and the KKC Agreement, and $9.9 million to remaining services revenue from the terminated Navire-BMS License Agreement. Revenue for the three months ended September 30, 2024 was $2.7 million, consisting mainly of services revenue under those agreements.

  3. How did the company's operating expenses change in 2024?

    Selling, general and administrative expenses rose to $194.1 million for the nine months from $103.0 million, mainly from commercialization readiness costs and $16.5 million of nonrecurring deal-related expenses. Research and development expenses rose to $376.1 million from $325.5 million, mainly from higher personnel and external costs for key programs. Restructuring, impairment and related charges were $10.9 million for the nine months, and the company expects an additional $6.0 million to $8.0 million of restructuring charges.

  4. What are the key debt obligations and covenants?

    The company had $747.5 million principal of 2.25% 2029 Notes and $550.0 million principal of 2.50% 2027 Notes, both convertible. It also had a $450.0 million term loan under the Amended Financing Agreement bearing variable interest, with principal payments of $22.5 million beginning June 30, 2027 and a stated maturity of January 17, 2029. The agreement requires a minimum unrestricted qualified cash balance of $70.0 million plus 40% of any cash released from escrow, which was $78.0 million as of September 30, 2024.

  5. How much cash is restricted, and when can it be released?

    Restricted cash was $139.4 million at September 30, 2024, primarily $139.3 million held in escrow accounts under the Amended Financing Agreement. The escrow funds arise from asset sales, with 75% of net proceeds required to be deposited. Between June 20, 2024 and the earlier of FDA approval of a first NDA for acoramidis or November 30, 2024, the company may request release of up to 50% of the original net cash proceeds. As of September 30, 2024, $20.0 million had been released.